Enzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric Condition
June 27, 2022 08:00 ET
|
Enzyvant
CAMBRIDGE, Mass. and BASEL, Switzerland, June 27, 2022 (GLOBE NEWSWIRE) -- Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced...
Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
April 21, 2022 08:00 ET
|
Enzyvant
CAMBRIDGE, Mass. and BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced...
Enzyvant Appoints Johanna Rossell as Chief Commercial Officer
January 26, 2022 08:00 ET
|
Enzyvant
CAMBRIDGE, Mass. and BASEL, Switzerland, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Enzyvant today announced the appointment of Johanna Rossell as Chief Commercial Officer. Johanna Rossell has an...
Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
October 08, 2021 20:09 ET
|
Enzyvant
RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia Children with congenital athymia are born without a thymus...
Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia
August 26, 2021 09:00 ET
|
Enzyvant
On average, pediatric congenital athymia patients spent 150.6 days each year in the hospital with a mean total cost of $5,534,121 for supportive care over three years Mean total costs for...
Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)
August 04, 2021 09:49 ET
|
Enzyvant
Kaplan-Meier estimated survival at one year and two years post treatment with investigational RVT-802 was 77% and 76%, respectively Follow-up time in the Efficacy Analysis Set (EAS) ranged from 0...
ENZYVANT Resubmits Biologics Licensing Application (BLA) to FDA for RVT-802 for Pediatric Congenital Athymia
April 27, 2021 06:00 ET
|
Enzyvant
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Enzyvant today announced the resubmission of the Biologics Licensing Application (BLA) to the U.S. Food and Drug Administration (FDA) for...